Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | USP7 | Q93009 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22862939 | 1.00 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2CA1CA2 | |
| SCHEMBL22862681 | 0.89 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2CA1CA2 | |
| SCHEMBL24704141 | 0.89 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2CA1CA2 | |
| SCHEMBL22862607 | 0.82 | SOS1 (0.44) | IDO1SOS1 | |
| SCHEMBL29490342 | 0.82 | SOS1 (0.44) | IDO1SOS1 | |
| SCHEMBL24704140 | 0.82 | SOS1 (0.44) | IDO1SOS1 | |
| SCHEMBL22862729 | 0.82 | CA1 (0.38) | NPC1RAB9ASMN1; SMN2CA1CA2 | |
| SCHEMBL22862435 | 0.82 | CA1 (0.42) | NPC1RAB9ASMN1; SMN2CA1CA2 | |
| SCHEMBL22862704 | 0.82 | CA1 (0.42) | NPC1RAB9ASMN1; SMN2CA1CA2 | |
| SCHEMBL22862431 | 0.80 | EGFR (0.39) | NPC1RAB9ASMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| EP-3976009-A2 | BAX INHIBITORS AND USES THEREOF | Case Western Reserve University (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | NPC1 1120/4885RAB9A 2006/4885SMN1; SMN2 1412/4885 |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | NPC1 2708/4885RAB9A 1715/4885SMN1; SMN2 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.